Biomolecules
Creating the future
From 10 to the power of 14 possibilities, we aim to create a groundbreaking single molecule.
An integrated platform to accelerate drug discovery.
Precisely preserves the natural structure.
Cell panning technology improves the acquisition rate of anti-GPCR antibodies.
We create high-quality VHH antibodies with high target specificity and excellent thermal stability.
Towards the development of highly accurate diagnostic drugs
Pairing with existing antibodies is also possible. We will search for the optimal combination.
We offer high-quality VHH antibodies optimized for immunochromatography.
Accelerate commercialization.
We offer licenses for VHH antibodies that are thermally stable and serve as cell growth factor substitutes.
Antibody drug discovery
- Join us in our quest to realize new treatments. We will support you every step of the way as your drug discovery partner, from obtaining proof of concept (PoC) to clinical development.
Diagnostic reagents
- We provide strong support for research and development, from the discovery to the evaluation of VHH antibodies. Our unique screening technology allows for rapid acquisition of candidates.
Next-generation cell manufacturing solutions
- Based on the functional antibody creation technology cultivated through drug discovery support, we are promoting the development of new solutions that evolve the cell manufacturing process itself.
cDNA display- Achieving diversity with a massive 10^13-14 library. Stable genotype-phenotype mapping technology.
Custom library- VHH antibody screening using the overwhelmingly diverse PharmaLogical® Library. Humanized design reduces immunogenicity.
Animal-free- Ethical and rapid antibody acquisition without the need for animal immunization. Screening is possible within 30 business days.
- 50+ Project Track Record
- 20+ Partner Companies and Universities
- 30Days Minimum acquisition period
News / Topics
- 2026.09.30
- 2026.09.15
- 2026.09.08
Technical Column
- 2026.07.27
- 2026.07.27
- 2026.07.27
Frequently asked questions (FAQ)
- Please tell me about the features of the VHH antibody library, "PharmaLogical Library."This is a humanized VHH artificial library designed for drug discovery, with improved structural stability and reduced immunogenicity risks. In particular, by significantly randomizing the CDR3, which is known to contribute most to antigen binding, it achieves a diversity of 10^13 to 10^14. For more details,Technical ColumnPlease refer to the published paper.
- Can I consult with you about antigen design?Yes. We will propose the optimal screening strategy, including antigen preparation methods, expression systems, and whether or not tags are used.
- Please explain the process leading up to the contract.After you contact us, we will sign a Non-Disclosure Agreement (NDA/CDA) and conduct an interview to understand your target audience and requirements. Following this, we will propose a screening strategy and a cost estimate, and the project will commence after the contract is signed.
- At what stage can I seek advice?We can assist you from the target selection stage. We provide support tailored to your R&D stage, from target selection and antigen design to screening strategy planning, functional evaluation, and modality development. Please feel free to contact us.
Start by requesting information.
Shall we get started?
Detailed information on VHH antibody research and development support is available for free download.
Material content
- About Us
- Drug Discovery Case Studies
- Technical Information
If you would like to consult directly, please click here.
→ Go to contact form